Balancing Benefit/Risk in the Dermatology Disease Space

Time: 11:15 am
day: Day Two


  • Considering whether the black box warning will stifle innovation across the JAK inhibitor class
  • Correlating disease severity and quality of life with off-target effects of JAK inhibitors
  • Rethinking how we define the black box warning to patients